Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | DHFR | P00374 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.48 |
| ▸ | CLPP | Q16740 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29888556 | 1.00 | KMT2A (0.55) | KMT2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL116582 | 0.89 | KMT2A (0.64) | KMT2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL1831804 | 0.86 | C5AR1 (0.60) | KMT2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL31095294 | 0.86 | C5AR1 (0.60) | KMT2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL16034465 | 0.85 | KMT2A (0.53) | KMT2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL30097663 | 0.85 | KMT2A (0.53) | KMT2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL15189148 | 0.85 | KMT2A (0.53) | KMT2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL5999840 | 0.85 | KMT2A (0.56) | KMT2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL29486422 | 0.84 | KMT2A (0.58) | KMT2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL19959258 | 0.84 | KMT2A (0.58) | KMT2AKDM4EALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107499-A1 | HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2023-04-06 | — | — | US | disclosed |
| CN-115348959-A | Heteroaryl compounds and their therapeutic use in disorders associated with altered beta-glucocerebrosidase activity | 增益治疗股份有限公司 | 2022-11-15 | — | — | CN | disclosed |
| EP-4065563-A1 | HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE | Gain Therapeutics SA (CH) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021105908-A1 | HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105908-A1 | HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2021-06-03 | — | — | WO | disclosed |
| US-10323032-B2 | P2X7 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-18 | — | — | US | disclosed |
| US-10323032-B2 | P2X7 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-18 | — | — | US | disclosed |
| EP-2812331-B1 | PIPERIDINO-PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-01-02 | — | — | EP | disclosed |
| EP-3321266-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-05-16 | — | — | EP | disclosed |
| EP-3321266-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-05-16 | — | — | EP | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1470122-B1 | RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053179-A1 | Rho-Kinase Inhibitors | CIT, ROCK1, ROCK2 | KMT2A 3704/4885KDM4E 1463/4885ALDH1A1 3690/4885 |
| US-10323032-B2 | P2X7 Modulators | P2RX7, P2RX1, P2RX3 | KMT2A 4469/4885KDM4E 3944/4885ALDH1A1 1245/4885 |
| US-20230107499-A1 | HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE | GBA1, GBA2, GBA3 | KMT2A 2603/4885KDM4E 4341/4885ALDH1A1 640/4885 |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | KMT2A 3704/4885KDM4E 1463/4885ALDH1A1 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.